Aju IB Investment

AJU IB Investment, founded in 1974, is a prominent South Korean venture capital and private equity firm, headquartered in Seoul’s Gangnam district. Known as one of the oldest VC firms in the country, AJU IB focuses on multi-stage investments spanning from early-stage startups to late-stage ventures and even buyouts. Their portfolio emphasizes industries like healthcare, life sciences, technology, and renewable energy. Key investments include companies such as Seer, Kymera Therapeutics, and Arcellx, showcasing their commitment to innovative, high-impact sectors. With over 270 investments under their belt, AJU IB Investment maintains a robust presence both in South Korea and the United States, aiming to scale businesses globally. They invest in diverse sectors, with recent activity concentrated on enterprise AI, healthcare tech, and digital therapeutics. Their approach often involves leading funding rounds while offering strategic guidance throughout the growth phases of their portfolio companies. AJU IB's seasoned leadership team, including CEO Ji-Won Kim and Managing Director Changsoo Yoon, ensures that they remain at the forefront of venture capital in Asia. Startups seeking to partner with AJU IB should prepare for a rigorous selection process, as the firm emphasizes scalability, strong business fundamentals, and innovative approaches within its chosen sectors. This focus has enabled them to secure exits in notable companies like Apellis Pharmaceuticals and Molecular Templates. AJU IB Investment continues to expand its global reach and impact.